Abstract
Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Current Pharmaceutical Biotechnology
Title: Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Volume: 7 Issue: 6
Author(s): H. De Raeve and K. Vanderkerken
Affiliation:
Keywords: immunomodulatory drugs, multiple myeloma, thalidomide, CC-5013, lenalidomide, CC-4047
Abstract: Thalidomide and the analogues lenalidomide (CC-5013, Revlimid®) and CC-4047 (Actimid®) belong to the family of immunomodulatory drugs (IMiDs). These agents have anti-angiogenic properties, modulate TNFα and IL-12 secretion, co-stimulate T cells, increase NK cell toxicity and have direct anti-tumour effects. These characteristics have made of them promising drugs for treatment of relapsed, refractory and newly diagnosed MM. It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFα and have, except for myelosuppression, less side effects than Thal. Combination of IMiDs with dexamethasone, bortezomib and with chemotherapeutic agents are tested in numerous trials, which will help in determining the optimal combination and administration schedule of different molecules to take advantage of non-overlapping toxicities and synergisms between those agents.
Export Options
About this article
Cite this article as:
De Raeve H. and Vanderkerken K., Immunomodulatory Drugs as a Therapy for Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116847
DOI https://dx.doi.org/10.2174/138920106779116847 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Utilization of Apatinib-Loaded Nanoparticles for the Treatment of Ocular Neovascularization
Current Drug Delivery Q Fever Endocarditis
Infectious Disorders - Drug Targets Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry Fluorescence Imaging of Tumors In Vivo
Current Medicinal Chemistry The Role of Metabolism in Toxicity of Polycyclic Aromatic Hydrocarbons and their Non-genotoxic Modes of Action
Current Drug Metabolism Design and Synthesis of Novel 1,3-Dioxane-2-carboxylic Acid Derivatives as PPARα/γ Dual Agonists
Letters in Drug Design & Discovery Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Anticancer Evaluation and Docking Study of New Bifunctional Phthalazine Derivatives
Current Organic Synthesis Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Polymer-Based Gene Delivery: A Current Review on the Uptake and Intracellular Trafficking of Polyplexes
Current Gene Therapy A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Microtubule-Stabilizing Natural Products as Promising Cancer Therapeutics
Current Medicinal Chemistry Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry